<DOC>
	<DOCNO>NCT00134966</DOCNO>
	<brief_summary>The purpose study achieve approval use carbidopa/levodopa/entacapone early Parkinson 's disease ( PD ) demonstrate use initial levodopa therapy early PD , carbidopa/levodopa/entacapone provide significantly great symptomatic benefit immediate release carbidopa/levodopa administer levodopa dosage level 100 mg three time day ( t.i.d . ) .</brief_summary>
	<brief_title>A Study Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa</brief_title>
	<detailed_description>The purpose study achieve approval use carbidopa/levodopa/entacapone early Parkinson 's disease ( PD ) demonstrate use initial levodopa therapy early PD , carbidopa/levodopa/entacapone provide significantly great symptomatic benefit immediate release carbidopa/levodopa administer levodopa dosage level 100 mg t.i.d .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Aged 30 80 year , inclusive , time Parkinson 's disease diagnosis Idiopathic Parkinson 's disease least 2 cardinal sign disease : resting tremor , bradykinesia rigidity Parkinson 's disease impairment warrant treatment levodopa formulation accord investigator 's assessment History , sign symptom suggest diagnosis atypical secondary Parkinsonism due drug , metabolic disorder , encephalitis neurodegenerative disease History stereotaxic brain surgery PD ( e.g. , pallidotomy , deep brain stimulation , tissue transplant ) Diagnosis Parkinson 's disease 5 year prior Screening Previous use levodopa formulation , entacapone tolcapone 30 day anytime within 4 week ( 28 day ) prior baseline Use dopamine agonist within 4 week ( 28 day ) prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Parkinson 's disease , levodopa , dyskinesia</keyword>
</DOC>